Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) – Research analysts at William Blair reduced their Q2 2022 earnings per share estimates for Axsome Therapeutics in a report released on Monday, May 2nd. William Blair analyst M. Minter now anticipates that the company will post earnings of ($1.05) per share for the quarter, down from their prior forecast of ($0.93). William Blair also issued estimates for Axsome Therapeutics’ Q3 2022 earnings at ($1.16) EPS, Q4 2022 earnings at ($1.14) EPS, FY2022 earnings at ($3.35) EPS, Q1 2023 earnings at ($0.56) EPS, Q2 2023 earnings at ($0.42) EPS, Q3 2023 earnings at ($0.25) EPS, Q4 2023 earnings at ($0.03) EPS, FY2023 earnings at ($1.26) EPS and FY2024 earnings at $5.82 EPS.
A number of other research firms have also recently issued reports on AXSM. StockNews.com started coverage on Axsome Therapeutics in a report on Thursday, March 31st. They issued a “sell” rating for the company. Zacks Investment Research cut shares of Axsome Therapeutics from a “buy” rating to a “hold” rating and set a $32.00 target price on the stock. in a report on Friday, March 4th. SVB Leerink cut their price objective on shares of Axsome Therapeutics from $65.00 to $50.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 2nd. Mizuho cut their target price on shares of Axsome Therapeutics from $51.00 to $49.00 in a research report on Tuesday. Finally, Jefferies Financial Group increased their price objective on shares of Axsome Therapeutics from $71.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, March 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Axsome Therapeutics currently has a consensus rating of “Buy” and an average target price of $80.58.
Axsome Therapeutics (NASDAQ:AXSM – Get Rating) last issued its quarterly earnings results on Monday, May 2nd. The company reported ($1.03) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.00) by ($0.03). During the same quarter in the prior year, the firm earned ($0.78) earnings per share.
Institutional investors have recently made changes to their positions in the company. Morgan Stanley lifted its stake in shares of Axsome Therapeutics by 122.8% in the second quarter. Morgan Stanley now owns 317,446 shares of the company’s stock valued at $21,414,000 after purchasing an additional 174,980 shares during the period. Commonwealth Equity Services LLC purchased a new stake in Axsome Therapeutics in the third quarter valued at approximately $491,000. Cambridge Investment Research Advisors Inc. increased its position in Axsome Therapeutics by 51.8% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 11,440 shares of the company’s stock worth $377,000 after purchasing an additional 3,905 shares in the last quarter. Deutsche Bank AG lifted its position in Axsome Therapeutics by 73.7% during the 3rd quarter. Deutsche Bank AG now owns 80,227 shares of the company’s stock worth $2,645,000 after acquiring an additional 34,029 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its position in Axsome Therapeutics by 42.3% in the 3rd quarter. Advisor Group Holdings Inc. now owns 5,901 shares of the company’s stock valued at $195,000 after buying an additional 1,754 shares during the last quarter. 48.46% of the stock is currently owned by institutional investors and hedge funds.
Axsome Therapeutics Company Profile (Get Rating)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.
- Get a free copy of the StockNews.com research report on Axsome Therapeutics (AXSM)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.